AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$HALO

Torley Helen sold $27K of HALO

Torley Helen (PRESIDENT AND CEO) sold 400 shares of HALOZYME THERAPEUTICS, INC. (HALO) at $66.37 on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Torley Helen
Published Jun 4, 2026, 12:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HALO
Neutral
medium confidence
Mentioned
$HALO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HALONeutralLow
01

Why it matters

The CEO’s disclosed sale can influence short-term sentiment, but 10b5-1 plans are designed to reduce timing-based inference.

02

Market read

A routine 10b5-1 insider sale is usually not a standalone trading catalyst; watch for follow-on filings or other HALO-specific news.

03

What to watch

Traders may overweight the headline; the key is whether there are concurrent non-10b5-1 sales, large option exercises/sales, or other contemporaneous HALO catalysts (earnings, trial updates, financing).

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-03; sale disclosed immediately after transaction date.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Halozyme Therapeutics (HALO).

Company-level read

Ticker impact

$HALONeutralMedium confidence
Context

SEC Form 4 shows HALO’s CEO sold 400 shares at $66.3680 on 2026-06-03 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine, pre-arranged open-market sale with a small dollar value relative to typical market moves and no accompanying operational/financial disclosure.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations; any dip could be overdone.

Key entities

  • issuer
    HALOZYME THERAPEUTICS, INC.

    Subject of the Form 4 insider transaction; CEO Torley Helen sold shares under a pre-arranged 10b5-1 plan.

  • insider
    Torley Helen

    President and CEO who sold 400 shares on 2026-06-03.

Read at source← All news

Related articles

AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min
AUG 7
$HALOHighAI 9/10

Halozyme climbs after record Q2 results and higher 2026 outlook

Halozyme Therapeutics (HALO) shares rose about 15% after the company reported record Q2 2026 results and raised 2026 guidance, according to Halozyme’s investor release. Q2 total revenue increased 48% to $481 million, royalty revenue rose 50% to $307.7 million. Full-year 2026 revenue guidance was raised to $1.835B-$1.910B and non-GAAP diluted EPS to $8.65-$9.00.

quiverquant.com4 min
AUG 7
$HALOHighAI 9/10

Why is Halozyme Therapeutics stock surging today?

Halozyme Therapeutics shares rose about 6.1% pre-open after the company reported record Q2 2026 results. Total revenue increased 48% to $481 million and non-GAAP EPS was $2.28, both above expectations. Royalty revenue hit $307.7 million. Halozyme raised full-year 2026 guidance to non-GAAP EPS of $8.65-$9.00 and revenue of $1.835-$1.910 billion, and said it signed five new ENHANZE/Hypercon deals year-to-date.

investing.com2 min
AUG 7
$HALOMedAI 8/10

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported Q2 royalty momentum for VYVGART Hytrulo, with royalty revenue up 143% to $72.6M and total VYVGART brand sales up 60% to $1.5B. Other royalty revenue rose 85% to $54.4M. Halozyme raised 2026 guidance to $1.835B-$1.91B revenue and $8.65-$9.00 non-GAAP EPS, and repurchased $332.8M of stock.

yahoo.com6 min